Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients with heart failure
The conference featured comprehensive discussions, field visits, and knowledge-sharing sessions addressing different aspect of major NCDs
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
The trademark rights for these brands will be transferred to Lupin by March next year.
Studies suggest that the protein Sclerostin plays a key role in the dysregulation of bone metabolism
Higher revenues backed by huge demand and expanding network contributed to the growth in bottom line
Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
Dyslipidemia is a critical risk factor for cardiovascular diseases
Subscribe To Our Newsletter & Stay Updated
